CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Nick Leschly, chief bluebird, will present at the 34th annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 4:00 p.m. PST. The conference is being held January 11-14, 2016 at the Westin St. Francis in San Francisco.
